| Toronto, Ontario. – February 21, 2006 – VisualSonics, the world’s leading developer of high-resolution, ultrasound-based, in vivo micro-imaging systems, today announced the appointment of Jonathan Lindner, MD, as Chief Molecular Advisor. Dr. Lindner, Associate Chief for Education, Cardiovascular Division, Oregon Health and Sciences University, will help oversee VisualSonics’ contrast-enhanced and molecular imaging strategies and activities.
A world-recognized leader in the fields of contrast-enhanced and molecular-based echocardiography, Dr. Lindner will help VisualSonics develop micro bubbles and molecular kits to be used with the Vevo 770™ micro-ultrasound platform. He will create protocols to use contrast agents in untargeted (ie. myocardial perfusion, tumor perfusion) and targeted (ie. inflammation target, angiogenic target) applications. In addition, Dr. Lindner will be involved in VisualSonics’ review of protocols and validation of biological targets.
“I’m pleased to work with VisualSonics as chief molecular advisor, a role that will allow me to demonstrate the benefits of micro-ultrasound in pre-clinical imaging, a modality that is currently underutilized when compared to its significant potential,” comments Jonathan Lindner, MD. “By adding molecular imaging capabilities to its micro-ultrasound technology, VisualSonics offers the only platform with high spatial and temporal resolution that simultaneously provides anatomical, functional, and molecular data. The research community needs to understand the benefits this platform can provide to a wide variety of in vivo applications.”
VisualSonics’ President and CEO Tom Little states, “As the company continues to grow, we are honored that Dr. Lindner will work closely with our organization’s molecular efforts.” He adds, “While VisualSonics is experiencing triple digit growth, we have penetrated only a tiny percentage of the $2.9B preclinical ultrasound imaging market and an incremental annual market potential of $300 million in preclinical contrast agent revenues. As Chief Molecular Advisor, Dr. Lindner will not only help expand the capabilities of the Vevo, but also help to educate the larger research community on the potential impact micro-ultrasound can have in a wide variety of research applications.
The announcement represents the latest development since the launch of the company’s molecular imaging program last month. In addition, the company recently released news of record growth and increased international demand, highlighted by the sale of the 200th Vevo system. In January, VisualSonics also announced ISO 9001:2000 registration.
About VisualSonics
VisualSonics is the world’s leading developer of high-resolution, ultrasound-based,
in vivo micro-imaging systems designed specifically for non-invasive small animal research. The company’s enabling micro-ultrasound technology, the Vevo 770, allows researchers at many of the world’s most prestigious pharmaceutical and biotechnology companies, hospitals and research centers to conduct genetic research, phenotypic study and drug development.
Micro-ultrasound is the fastest growing preclinical imaging modality. This enabling technology is facilitating research in cardiac and vascular disease, cancer, stem cell research and developmental biology. When compared to other imaging options, only micro-ultrasound has the combination of high-resolution, real-time imaging, in vivo detection and analysis, reasonable cost, ease of use, portability and no negative biological effects. More information on VisualSonics and micro-ultrasound can be found at www.visualsonics.com.
Contacts:
Jennifer Viera
Schwartz Communications
visualsonics@schwartz-pr.com
781/684-0770 |
|
| |
|
 |
|
|
|
